Nifty
Sensex
:
:
9915.25
32028.89
41.95 (0.42%)
124.49 (0.39%)

Pharmaceuticals & Drugs

Rating :
25/99

BSE: 500124 | NSE: DRREDDY

2762.55
12.45 (0.45%)
21-Jul-2017 | 3:50PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 2738.00
  • 2780.00
  • 2727.00
  • 2750.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 282516
  • 7804.65
  • 3689.85
  • 2380.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 45,536.03
  • 35.24
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 50,068.03
  • 0.73%
  • 3.74

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.79%
  • 3.06%
  • 8.34%
  • FII
  • DII
  • Others
  • 0.28%
  • 10.27%
  • 51.26%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
3,611.90
3,756.20
-3.84%
3,723.20
3,967.90
-6.17%
3,616.30
3,988.96
-9.34%
3,222.50
3,757.76
-14.24%
Expenses
3,021.40
3,279.70
-7.88%
2,858.70
3,222.30
-11.28%
2,989.30
3,095.17
-3.42%
2,832.30
2,999.08
-5.56%
EBITDA
590.50
476.50
23.92%
864.50
745.60
15.95%
627.00
893.79
-29.85%
390.20
758.68
-48.57%
EBIDTM
16.35%
12.69%
23.22%
18.79%
17.34%
22.41%
12.11%
20.19%
Other Income
20.50
30.70
-33.22%
40.30
12.20
230.33%
43.80
31.99
36.92%
67.00
34.12
96.37%
Interest
19.60
264.60
-92.59%
16.40
6.20
164.52%
12.60
21.64
-41.77%
14.80
0.00
0.00
Depreciation
254.30
0.00
0.00
266.50
0.00
0.00
262.20
0.00
0.00
243.60
0.00
0.00
PBT
337.10
242.60
38.95%
621.90
751.60
-17.26%
396.00
904.14
-56.20%
198.80
792.80
-74.92%
Tax
9.70
173.90
-94.42%
138.50
178.80
-22.54%
95.60
187.88
-49.12%
52.60
172.07
-69.43%
PAT
327.40
68.70
376.56%
483.40
572.80
-15.61%
300.40
716.26
-58.06%
146.20
620.73
-76.45%
PATM
9.06%
1.83%
12.98%
14.44%
8.31%
17.96%
4.54%
16.52%
EPS
20.36
4.37
365.90%
29.69
33.95
-12.55%
18.63
42.32
-55.98%
9.27
36.68
-74.73%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
14,196.10
15,697.80
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
4,991.80
Net Sales Growth
-9.57%
4.49%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
38.24%
 
Cost Of Goods Sold
3,444.90
3,540.70
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
1,601.20
Gross Profit
10,751.20
12,157.10
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
3,390.60
GP Margin
75.73%
77.44%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
67.92%
Total Expenditure
11,723.90
11,777.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
4,155.10
Power & Fuel Cost
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
97.60
% Of Sales
2.33%
2.01%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
1.96%
Employee Cost
3,106.80
3,187.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
731.00
% Of Sales
21.88%
20.30%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
14.64%
Manufacturing Exp.
2,138.20
2,148.90
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
768.40
% Of Sales
15.06%
13.69%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
15.39%
General & Admin Exp.
1,339.90
1,275.70
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
395.80
% Of Sales
9.44%
8.13%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
7.93%
Selling & Distn. Exp.
1,293.40
1,239.00
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
523.30
% Of Sales
9.11%
7.89%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
10.48%
Miscellaneous Exp.
70.60
70.10
65.70
35.60
38.50
85.20
147.00
150.80
183.60
523.30
% Of Sales
0.50%
0.45%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
0.76%
EBITDA
2,472.20
3,920.80
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
836.70
EBITDA Margin
17.41%
24.98%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
16.76%
Other Income
171.50
269.30
274.10
169.90
149.90
132.30
52.30
103.10
99.40
214.10
Interest
63.40
82.40
108.20
126.70
100.30
114.10
32.30
38.50
108.20
102.20
Depreciation
1,026.60
970.50
759.90
647.50
550.20
518.10
398.10
413.10
497.70
401.90
PBT
1,553.70
3,137.20
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
546.70
Tax
296.50
523.70
563.20
683.10
637.90
503.50
183.90
266.80
260.80
107.70
Tax Rate
19.08%
19.58%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
19.70%
PAT
1,257.20
2,151.40
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.80
PAT before Minority Interest
1,257.20
2,151.40
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
439.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.80
PAT Margin
8.86%
13.71%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
8.81%
PAT Growth
-41.56%
-7.92%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
-308.53%
 
Unadjusted EPS
77.53
126.15
137.18
115.45
89.93
76.76
59.06
20.83
-54.48
26.07

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,262.10
11,700.90
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
4,496.90
Share Capital
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
84.10
Total Reserves
12,098.80
11,525.50
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
4,377.60
Non-Current Liabilities
456.10
1,187.40
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
2,049.00
Secured Loans
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
64.20
Unsecured Loans
485.20
994.30
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
1,904.20
Long Term Provisions
84.20
94.70
77.90
56.30
51.40
33.30
28.80
0.00
0.00
0.00
Current Liabilities
8,419.90
6,836.80
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
1,150.80
Trade Payables
1,056.90
930.90
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
1,027.50
Other Current Liabilities
2,339.70
2,439.50
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
5.80
Short Term Borrowings
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
0.00
Short Term Provisions
660.70
1,194.60
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
117.50
Total Liabilities
21,138.10
19,725.10
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70
Net Block
6,930.70
6,563.40
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
3,912.50
Gross Block
15,932.40
15,102.20
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
5,487.80
Accumulated Depreciation
8,961.40
8,523.30
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
1,575.30
Non Current Assets
11,454.40
7,905.00
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
4,312.20
Capital Work in Progress
3,324.50
663.10
529.00
638.80
565.30
708.50
575.20
762.20
429.60
268.40
Non Current Investment
682.60
145.60
145.60
0.40
0.40
0.90
0.90
0.60
0.60
131.30
Long Term Loans & Adv.
482.10
519.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
0.00
Other Non Current Assets
34.50
13.50
6.40
0.00
20.90
0.00
0.00
0.00
0.00
0.00
Current Assets
9,683.70
11,820.10
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
3,384.50
Current Investments
1,427.10
2,112.20
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
350.80
Inventories
2,852.80
2,579.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
1,101.90
Sundry Debtors
3,798.60
4,166.70
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
652.20
Cash & Bank
386.50
1,835.80
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
744.70
Other Current Assets
1,218.70
187.80
226.20
170.40
961.90
705.80
879.60
660.90
551.90
534.90
Short Term Loans & Adv.
767.20
937.70
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
532.10
Net Current Assets
1,263.80
4,983.30
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
2,233.70
Total Assets
21,138.10
19,725.10
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
7,696.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,144.40
4,047.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
512.80
PBT
1,553.70
2,675.10
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
545.00
Adjustment
1,692.70
2,099.90
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
523.40
Changes in Working Capital
-525.00
-17.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
-402.40
Cash after chg. in Working capital
2,721.40
4,757.50
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
666.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-577.00
-709.90
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
-153.20
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,840.40
-1,942.10
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
-810.40
Net Fixed Assets
-1,029.50
-1,882.00
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
-424.90
Net Investments
786.40
-26.00
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
-1,100.39
Others
-1,597.30
-34.10
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
714.89
Cash from Financing Activity
-369.20
-1,700.90
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
-775.40
Net Cash Inflow / Outflow
-65.20
404.60
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
-1,073.00
Opening Cash & Equivalents
492.10
582.90
862.40
520.40
736.20
573.00
660.00
562.30
744.70
1,861.00
Closing Cash & Equivalent
377.80
558.70
582.90
862.40
520.40
736.20
575.10
660.00
562.30
744.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
734.72
680.59
572.92
457.33
371.04
290.91
235.90
221.67
207.08
265.26
ROA
6.14%
11.30%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
5.70%
ROE
10.20%
20.13%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
10.41%
ROCE
9.77%
18.87%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
10.02%
Fixed Asset Turnover
0.92
1.14
1.23
1.23
1.26
1.17
1.04
1.09
1.16
0.99
Receivable days
101.86
95.61
89.72
87.97
87.19
79.59
70.77
67.20
55.01
51.82
Inventory Days
69.56
59.55
60.27
62.06
62.74
65.60
71.20
68.85
63.79
66.85
Payable days
31.00
28.47
28.48
33.96
34.99
35.37
72.19
108.29
85.61
85.15
Cash Conversion Cycle
140.42
126.69
121.51
116.06
114.93
109.82
69.78
27.76
33.19
33.52
Total Debt/Equity
0.40
0.29
0.44
0.58
0.58
0.66
0.59
0.40
0.57
0.44
Interest Cover
25.51
33.46
27.80
21.89
22.58
16.81
37.62
17.06
-5.07
6.35

News Update


  • USFDA completes audit at Dr. Reddy’s API Cuernavaca plant in Mexico
    21st Jul 2017, 11:09 AM

    The USFDA has completed the Audit for the same with Zero observation

    Read More
  • Dr. Reddy’s Laboratories launches Vozet Tablets in Indian market
    19th Jul 2017, 10:02 AM

    The drug is indicated for the treatment of allergic Rhinitis and chronic Urticaria

    Read More
  • Dr. Reddy’s gets USFDA observations for Srikakulam facility
    17th Jun 2017, 09:50 AM

    The pharma major has been issued a Form 483 with one observation, which it is addressing

    Read More
  • Dr. Reddy’s recalls 3.25 lakh cartons of Zenatane capsules from US
    15th Jun 2017, 08:52 AM

    The drug is manufactured by pharma firm Cipla at its Pune facility for Dr Reddy’s Laboratories

    Read More
  • Dr. Reddy’s receives EIR from USFDA for Miryalaguda facility
    14th Jun 2017, 08:54 AM

    Miryalaguda plant supplies active ingredients for company’s captive consumption as well as for its customers

    Read More
  • Dr. Reddy’s Laboratories launches Bivalirudin for Injection in US market
    6th Jun 2017, 11:33 AM

    Dr. Reddy’s Bivalirudin Injection, 250 mg/vial, are available in packages of 10 single-dose vials

    Read More
  • Dr. Reddy’s successfully completes USFDA audit for Srikakulum Plant
    26th May 2017, 09:10 AM

    USFDA has completed the audit on May 25, 2017 with zero observations

    Read More
  • Dr. Reddy’s partners DST, UoH to develop anti-psoriatic drugs
    24th May 2017, 11:42 AM

    The three entities have inked an agreement for the same

    Read More
  • Dr Reddy’s receives approval for Doxorubicin Hydrochloride Liposome Injection launch
    17th May 2017, 13:49 PM

    The company has received approval from the USFDA to launch Doxorubicin Hydrochloride Liposome Injection in the US

    Read More
  • Dr Reddy’s Labs launches generic sofosbuvir & velpatasvir tablets
    16th May 2017, 09:42 AM

    The tablets are available in bottle count size of 28

    Read More
  • Dr. Reddy's Laboratories reports around three fold rise in Q4 consolidated net profit
    12th May 2017, 15:27 PM

    Total income of the company decreased by 6.38% at Rs 3632.40 crore for quarter under review

    Read More
  • Dr. Reddys Lab - Quarterly Results
    12th May 2017, 13:49 PM

    Read More
  • Dr. Reddy’s gets 11 USFDA observations for Bachupally facility
    29th Apr 2017, 09:11 AM

    These observations are mostly procedural in nature, reflecting the need to improve people capabilities and strengthen documentation and laboratory systems

    Read More
  • Dr. Reddy's Laboratories launches Ezetimibe & Simvastatin Tablets in the US Market
    27th Apr 2017, 10:21 AM

    Dr. Reddy's Ezetimibe and Simvastatin Tablets are available in bottle count sizes of 30, 90 and 1000

    Read More
  • Dr. Reddy’s launches Progesterone Capsules is US markets
    22nd Apr 2017, 10:40 AM

    The company’s Progesterone Capsules, 100 mg and 200 mg, are available in bottle count size of 100

    Read More
  • Dr. Reddy’s completes USFDA audit for Srikakulam API manufacturing facility
    15th Apr 2017, 08:32 AM

    USFDA has completed the audit of the said plant on April 14, 2017 with no observations

    Read More
  • Dr. Reddy's recalls 1,728 bottles of Rivastigmine Tartrate capsules from US
    14th Apr 2017, 09:51 AM

    The company's US arm, Dr. Reddy’s Laboratories Inc is recalling Rivastigmine Tartrate capsules 1.5 mg in 60-count bottle manufactured by Dr. Reddy’s Laboratories in India

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.